Prostate Cancer

Which prostate cancer patients will respond to experimental therapy?

Published in Cancer Weekly, January 11th, 2005

Researchers at UCLA's Jonsson Cancer Center have identified for the first time a way to predict which prostate cancer patients will benefit from an experimental therapy that blocks a cell signaling pathway responsible for driving the growth of the cancer.

The discovery, which appears in the peer-reviewed journal Clinical Cancer Research, may allow oncologists to customize "targeted" cancer treatments for each patient based on the molecular make-up of their tumors. These "smart drugs" selectively stop the growth of tumor cells with the molecular abnormality. This is in striking contrast to chemotherapy drugs, which are not administered on the basis of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry